ES2186340T3 - Utilizacion de polipeptidos fgf-5 para la prevencion de la muerte de neuronas retinales y para el tratamiento de enfermedades oculares. - Google Patents

Utilizacion de polipeptidos fgf-5 para la prevencion de la muerte de neuronas retinales y para el tratamiento de enfermedades oculares.

Info

Publication number
ES2186340T3
ES2186340T3 ES99912439T ES99912439T ES2186340T3 ES 2186340 T3 ES2186340 T3 ES 2186340T3 ES 99912439 T ES99912439 T ES 99912439T ES 99912439 T ES99912439 T ES 99912439T ES 2186340 T3 ES2186340 T3 ES 2186340T3
Authority
ES
Spain
Prior art keywords
retinal
retinopathies
polypeptides
fgf
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES99912439T
Other languages
English (en)
Inventor
Ivar J Kljavin
Fleur Monique La
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/240,952 external-priority patent/US6331523B1/en
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ES2186340T3 publication Critical patent/ES2186340T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Utilización de un polipéptido activo de FGF-5 en la preparación de un medicamento para retrasar, prevenir o rescatar las células de la retina de la lesión o de la muerte celular.
ES99912439T 1998-03-12 1999-03-10 Utilizacion de polipeptidos fgf-5 para la prevencion de la muerte de neuronas retinales y para el tratamiento de enfermedades oculares. Expired - Lifetime ES2186340T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4138398A 1998-03-12 1998-03-12
US09/240,952 US6331523B1 (en) 1998-03-12 1999-01-29 Method of enhancing the survival of retinal neurons and treating ocular diseases using FGF-5

Publications (1)

Publication Number Publication Date
ES2186340T3 true ES2186340T3 (es) 2003-05-01

Family

ID=26718088

Family Applications (1)

Application Number Title Priority Date Filing Date
ES99912439T Expired - Lifetime ES2186340T3 (es) 1998-03-12 1999-03-10 Utilizacion de polipeptidos fgf-5 para la prevencion de la muerte de neuronas retinales y para el tratamiento de enfermedades oculares.

Country Status (9)

Country Link
EP (1) EP1061943B1 (es)
JP (2) JP3764047B2 (es)
AT (1) ATE226444T1 (es)
AU (1) AU754380B2 (es)
CA (1) CA2322380C (es)
DE (1) DE69903612T2 (es)
ES (1) ES2186340T3 (es)
IL (1) IL138033A0 (es)
WO (1) WO1999045952A2 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3755900A (en) * 1999-03-15 2000-10-04 Chiron Corporation Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
US6943153B1 (en) 1999-03-15 2005-09-13 The Regents Of The University Of California Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
JP2003511388A (ja) * 1999-10-02 2003-03-25 アメリカ合衆国 繊維芽細胞増殖因子−５（ｆｇｆ−５）は腫瘍関連ｔ細胞抗原である
EP2301549A1 (en) * 2003-04-18 2011-03-30 Advanced Medicine Research Institute Remedies for diseases to be applied to eye
JP2008064459A (ja) * 2004-12-24 2008-03-21 Univ Kurume 色素上皮由来因子の定量法
US7947274B2 (en) 2007-01-04 2011-05-24 Humabs, LLC. Human cytomegalovirus neutralising antibodies and use thereof
GB0700133D0 (en) 2007-01-04 2007-02-14 Humabs Llc Human cytomegalovirus neutralising antibodies and use thereof
PE20141435A1 (es) 2008-07-16 2014-10-22 Inst Research In Biomedicine Anticuerpos neutralizantes de citomegalovirus humano
TWI775096B (zh) 2012-05-15 2022-08-21 澳大利亞商艾佛蘭屈澳洲私營有限公司 使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd)
JP6628252B2 (ja) * 2014-02-28 2020-01-08 国立大学法人京都大学 虚血性眼疾患の処置用の医薬組成物
KR102537394B1 (ko) 2014-03-17 2023-05-30 애드베룸 바이오테크놀로지스, 인코포레이티드 원추세포에서 증강된 유전자 발현을 위한 조성물 및 방법
MY187898A (en) 2015-03-02 2021-10-27 Adverum Biotechnologies Inc Compositions and methods for intravitreal delivery of polynucleotides to retinal cones
GB2545763A (en) 2015-12-23 2017-06-28 Adverum Biotechnologies Inc Mutant viral capsid libraries and related systems and methods

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994020125A1 (en) * 1993-03-12 1994-09-15 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Treatment of motor neuron diseases with fibroblast growth factor-5 (fgf-5)
EP0776218A2 (en) * 1994-03-15 1997-06-04 Prizm Pharmaceuticals, Inc. Heparin-binding growth factors for gene therapy and anterior eye disorders
US5629284A (en) * 1995-07-24 1997-05-13 Meiji Milk Products Co., Ltd. Method for treating retinal diseases
UA75316C2 (uk) * 1996-10-16 2006-04-17 Займодженетікс, Інк. Гомологи з фактором росту фібробласта

Also Published As

Publication number Publication date
JP3764047B2 (ja) 2006-04-05
DE69903612T2 (de) 2003-07-10
JP2002526381A (ja) 2002-08-20
EP1061943B1 (en) 2002-10-23
IL138033A0 (en) 2001-10-31
ATE226444T1 (de) 2002-11-15
AU754380B2 (en) 2002-11-14
EP1061943A1 (en) 2000-12-27
DE69903612D1 (de) 2002-11-28
WO1999045952A2 (en) 1999-09-16
AU3081399A (en) 1999-09-27
CA2322380A1 (en) 1999-09-16
WO1999045952A3 (en) 2000-11-23
CA2322380C (en) 2008-10-14
JP2006089489A (ja) 2006-04-06

Similar Documents

Publication Publication Date Title
WO2001009327A3 (en) Method of preventing the injury or death of retinal cells and treating ocular diseases
ES2186340T3 (es) Utilizacion de polipeptidos fgf-5 para la prevencion de la muerte de neuronas retinales y para el tratamiento de enfermedades oculares.
Fernández-Albarral et al. Glaucoma: from pathogenic mechanisms to retinal glial cell response to damage
Ahmed et al. Minocycline modulates microglia polarization in ischemia-reperfusion model of retinal degeneration and induces neuroprotection
Valiente-Soriano et al. BDNF rescues RGCs but not intrinsically photosensitive RGCs in ocular hypertensive albino rat retinas
NO982275D0 (no) FremgangsmÕter for behandling av fotoreseptorer under anvendelse av proteinprodukt av gliacellelinjeavledet neurotrof faktor (GDNF)
WO2021178237A3 (en) Oligonucleotide compositions and methods thereof
WO2020219983A3 (en) Oligonucleotide compositions and methods of use thereof
WO2023076352A3 (en) Oligonucleotide compositions and methods of use thereof
KR890003387A (ko) 국소활성을 갖는 이중-가닥 RMAs조성물
WO2000053760A3 (en) Method of preventing the death of retinal neurons and treating ocular diseases
Eong et al. Cytomegalovirus retinitis in patients with acquired immune deficiency syndrome
Abe et al. Lens epithelial changes and mutated gene expression in patients with myotonic dystrophy
FR2393579A1 (fr) Agent antiviral et son application au traitement des affections virales
US5629284A (en) Method for treating retinal diseases
EP0083261B1 (fr) Composition thérapeutique, à base d'inosine monophosphaté, pour le traitement des troubles d'accommodation de l'oeil
Bernhard et al. Chronic ulcerating acyclovir-resistant varicella zoster lesions in an AIDS patient
EP1059931B1 (de) Verwendung von cd137 zur förderung der proliferation peripherer monocyten
Travers et al. A controlled trial of adenine arabinoside and trifluorothymidine in herpetic keratitis
Møller et al. Early treatment of granular dystrophy (Groenouw type I)
Shiota Clinical evaluation of acyclovir in the treatment of ulcerative herpetic keratitis
Rotman et al. Two asymptomatic plaques on the chest of a young woman
Scopula I Department of Aerospace Medicine, USAF School of Aerospace Medi-I cine, 2513 Kennedy Circle, Brooks AFB, TX 78235-5123 I
MUKHAMEDOVA et al. STUDY OF SIDE EFFECTS OF VIRAL INFECTION ON EYE ORGANS
NIDES THOMAS, C., CORDIER, J., WATRIN, E.